Zygomycosis

 

 Buy Article Permissions and Reprints

Zygomycosis is an invasive mycotic disease caused by fungi in the class Zygomycetes. Within this class, the most common species associated with infection include Absidia corymbifera, Apophysomyces elegans, Cunninghamella bertholletiae, Rhizomucor pusillus, Rhizopus microsporus var. rhizopodiformis, and Rhizopus arrhizus. These fungi all produce characteristic hyphal forms in tissue that are variable in width, produce haphazard branching, and lack septation. Although these fungi are ubiquitous in the environment, they are opportunists causing invasive disease in compromised hosts with a high mortality even when aggressive antifungal therapy and surgical intervention are utilized. Clinically, the disease most often affects the sinus with or without pulmonary involvement; direct extension from sinuses into cerebral tissue is not uncommon. This article describes the general clinical features of zygomycosis, with an emphasis on management in the setting of immunosuppression.

REFERENCES

• 1 Lee F Y, Mossad S B, Adal K A. Pulmonary mucormycosis: the last 30 years.  Arch Intern Med. 1999;  159 1301-1309
  CrossrefPubMedGoogle Scholar
• 2 Kwon-Chung K J, Bennett J E. Mucormycosis. In: Cann C Medical Mycology. Philadelphia; Lea & Febiger 1992: 524-559
  Google Scholar
• 3 Ribes J A, Vanover-Sams C L, Baker D J. Zygomycetes in human disease.  Clin Microbiol Rev. 2000;  13 236-301
  CrossrefPubMedGoogle Scholar
• 4 Sugar A. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R Principles and Practice of Infectious Diseases. Vol 2. 5th ed. Philadelphia; Churchill Livingstone; 2000: 2685-2694
  Google Scholar
• 5 Belin L. Sawmill alveolitis in Sweden.  Int Arch Allergy Appl Immunol. 1987;  82 440-443
  PubMedGoogle Scholar
• 6 Wimander K, Belin L. Recognition of allergic alveolitis in the trimming department of a Swedish sawmill.  Eur J Respir Dis Suppl. 1980;  107 163-167
  PubMedGoogle Scholar
• 7 Waldorf A R. Pulmonary defense mechanisms against opportunistic fungal pathogens.  Immunol Ser. 1989;  47 243-271
  PubMedGoogle Scholar
• 8 Diamond R D, Clark R A. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro.  Infect Immun. 1982;  38 487-495
  PubMedGoogle Scholar
• 9 Waldorf A R, Ruderman N, Diamond R D. Specific susceptibility of mucormycosis in murine diabetes and broncholaveolar macrophage defense against Rhizopus .  J Clin Invest. 1984;  74 150-160
  CrossrefPubMedGoogle Scholar
• 10 Artis W M, Fountain J A, Delcher H K, Jones H E. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability.  Diabetes. 1982;  31 1109-1114
  CrossrefPubMedGoogle Scholar
• 11 Bagdade J D. Phagocytic and microbicidal function in diabetes mellitus.  Acta Endocrinol Suppl (Copenh). 1976;  205 27-34
  PubMedGoogle Scholar
• 12 Meyer R D, Rosen P, Armstrong D. Phycomycosis complicating leukemia and lymphoma.  Ann Intern Med. 1972;  77 871-879
  PubMedGoogle Scholar
• 13 Kontoyiannis D P, Wessel V C, Bodey G P, Rolston K V. Zygomycosis in the 1990s in a tertiary-care cancer center.  Clin Infect Dis. 2000;  30 851-856
  CrossrefPubMedGoogle Scholar
• 14 Marr K A, Carter R A, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.  Clin Infect Dis. 2002;  34 909-917
  CrossrefPubMedGoogle Scholar
• 15 Windus D W, Stokes T J, Julian B A, Fenves A Z. Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine.  Ann Intern Med. 1987;  107 678-680
  PubMedGoogle Scholar
• 16 Daly A L, Velazquez L A, Bradley S F, Kauffman C A. Mucormycosis: association with deferoxamine therapy.  Am J Med. 1989;  87 468-471
  PubMedGoogle Scholar
• 17 Eiser A R, Slifkin R F, Neff M S. Intestinal mucormycosis in hemodialysis patients following deferoxamine.  Am J Kidney Dis. 1987;  10 71-73
  PubMedGoogle Scholar
• 18 Singh N, Gayowski T, Singh J, Yu V L. Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients.  Clin Infect Dis. 1995;  20 617-620
  PubMedGoogle Scholar
• 19 Paparello S F, Parry R L, MacGillivray D C, Brock N, Mayers D L. Hospital-acquired wound mucormycosis.  Clin Infect Dis. 1992;  14 350-352
  PubMedGoogle Scholar
• 20 Song W K, Park H J, Cinn Y W et al.. Primary cutaneous mucormycosis in a trauma patient.  J Dermatol. 1999;  26 825-828
  PubMedGoogle Scholar
• 21 Sharma R R, Pawar S J, Delmendo A, Lad S D, Athale S D. Fatal rhino-orbito-cerebral mucormycosis in an apparently normal host: case report and literature review.  J Clin Neurosci. 2001;  8 583-586
  CrossrefPubMedGoogle Scholar
• 22 Mitchell S J, Gray J, Morgan M E, Hocking M D, Durbin G M. Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors.  Lancet. 1996;  348 441-443
  CrossrefPubMedGoogle Scholar
• 23 Oh D, Notrica D. Primary cutaneous mucormycosis in infants and neonates: case report and review of the literature.  J Pediatr Surg. 2002;  37 1607-1611
  CrossrefPubMedGoogle Scholar
• 24 Hejny C, Kerrison J B, Newman N J, Stone C M. Rhino-orbital mucormycosis in a patient with acquired immunodeficiency syndrome (AIDS) and neutropenia.  Am J Ophthalmol. 2001;  132 111-112
  CrossrefPubMedGoogle Scholar
• 25 Sanchez M R, Ponge-Wilson I, Moy J A, Rosenthal S. Zygomycosis and HIV infection.  J Am Acad Dermatol. 1994;  30(5 pt 2) 904-908
  PubMedGoogle Scholar
• 26 Gonzalez C E, Rinaldi M G, Sugar A M. Zygomycosis.  Infect Dis Clin North Am. 2002;  16 895-914
  CrossrefPubMedGoogle Scholar
• 27 Rangel-Guerra R A, Martinez H R, Saenz C, Bosques-Padilla F, Estrada-Bellmann I. Rhinocerebral and systemic mucormycosis: clinical experience with 36 cases.  J Neurol Sci. 1996;  143 19-30
  CrossrefPubMedGoogle Scholar
• 28 Pagano L, Ricci P, Tonso A et al.. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto).  Br J Haematol. 1997;  99 331-336
  CrossrefPubMedGoogle Scholar
• 29 Gaziev D, Baronciani D, Galimberti M et al.. Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature.  Bone Marrow Transplant. 1996;  17 409-414
  PubMedGoogle Scholar
• 30 Ferguson B J. Mucormycosis of the nose and paranasal sinuses.  Otolaryngol Clin North Am. 2000;  33 349-365
  CrossrefPubMedGoogle Scholar
• 31 Sohail M A, Al Khabori M, Hyder J, Verma A. Acute fulminant fungal sinusitis: clinical presentation, radiological findings and treatment.  Acta Trop. 2001;  80 177-185
  PubMedGoogle Scholar
• 32 Kyrmizakis D E, Doxas P G, Hajiioannou J K, Papadakis C E. Palate ulcer due to mucormycosis.  J Laryngol Otol. 2002;  116 146-147
  CrossrefPubMedGoogle Scholar
• 33 Blitzer A, Lawson W, Meyers B R, Biller H F. Patient survival factors in paranasal sinus mucormycosis.  Laryngoscope. 1980;  90 635-648
  PubMedGoogle Scholar
• 34 Tedder M, Spratt J A, Anstadt M P et al.. Pulmonary mucormycosis: results of medical and surgical therapy.  Ann Thorac Surg. 1994;  57 1044-1050
  CrossrefPubMedGoogle Scholar
• 35 Latif S, Saffarian N, Bellovich K, Provenzano R. Pulmonary mucormycosis in diabetic renal allograft recipients.  Am J Kidney Dis. 1997;  29 461-464
  PubMedGoogle Scholar
• 36 Demirag A, Elkhammas E A, Henry M L et al.. Pulmonary Rhizopus infection in a diabetic renal transplant recipient.  Clin Transplant. 2000;  14 8-10
  CrossrefPubMedGoogle Scholar
• 37 Veliath A J, Rao R, Prabhu M R, Aurora A L. Cutaneous phycomycosis (mucormycosis) with fatal pulmonary dissemination.  Arch Dermatol. 1976;  112 509-512
  CrossrefPubMedGoogle Scholar
• 38 Bigby T D, Serota M L, Tierney Jr L M, Matthay M A. Clinical spectrum of pulmonary mucormycosis.  Chest. 1986;  89 435-439
  PubMedGoogle Scholar
• 39 Pagano L, Ricci P, Nosari A et al.. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell'Adulto).  Br J Haematol. 1995;  89 500-505
  CrossrefPubMedGoogle Scholar
• 40 Husari A W, Jensen W A, Kirsch C M et al.. Pulmonary mucormycosis presenting as an endobronchial lesion.  Chest. 1994;  106 1889-1891
  CrossrefPubMedGoogle Scholar
• 41 Everett E D, Pearson S, Rogers W. Rhizopus surgical wound infection with elasticized adhesive tape dressings.  Arch Surg. 1979;  114 738-739
  PubMedGoogle Scholar
• 42 Adam R D, Hunter G, DiTomasso J, Comerci Jr G. Mucormycosis: emerging prominence of cutaneous infections.  Clin Infect Dis. 1994;  19 67-76
  PubMedGoogle Scholar
• 43 Alsuwaida K. Primary cutaneous mucormycosis complicating the use of adhesive tape to secure the endotracheal tube.  Can J Anaesth. 2002;  49 880-882
  PubMedGoogle Scholar
• 44 Bearer E A, Nelson P R, Chowers M Y, Davis C E. Cutaneous zygomycosis caused by Saksenaea vasiformis in a diabetic patient.  J Clin Microbiol. 1994;  32 1823-1824
  PubMedGoogle Scholar
• 45 Scalise A, Barchiesi F, Viviani M A et al.. Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot.  J Infect. 1999;  38 191-192
  CrossrefPubMedGoogle Scholar
• 46 Nomura J, Ruskin J, Sahebi F, Kogut N, Falk P M. Mucormycosis of the vulva following bone marrow transplantation.  Bone Marrow Transplant. 1997;  19 859-860
  CrossrefPubMedGoogle Scholar
• 47 Newton W D, Cramer F S, Norwood S H. Necrotizing fasciitis from invasive Phycomycetes.  Crit Care Med. 1987;  15 331-332
  PubMedGoogle Scholar
• 48 Lakshmi V, Rani T S, Sharma S et al.. Zygomycotic necrotizing fasciitis caused by Apophysomyces elegans .  J Clin Microbiol. 1993;  31 1368-1369
  PubMedGoogle Scholar
• 49 Mooney J E, Wanger A. Mucormycosis of the gastrointestinal tract in children: report of a case and review of the literature.  Pediatr Infect Dis J. 1993;  12 872-876
  PubMedGoogle Scholar
• 50 Carr E J, Scott P, Gradon J D. Fatal gastrointestinal mucormycosis that invaded the postoperative abdominal wall wound in an immunocompetent host.  Clin Infect Dis. 1999;  29 956-957
  PubMedGoogle Scholar
• 51 Vadeboncoeur C, Walton J M, Raisen J et al.. Gastrointestinal mucormycosis causing an acute abdomen in the immunocompromised pediatric patient: three cases.  J Pediatr Surg. 1994;  29 1248-1249
  CrossrefPubMedGoogle Scholar
• 52 Knoop C, Antoine M, Vachiery J L et al.. Gastric perforation due to mucormycosis after heart-lung and heart transplantation.  Transplantation. 1998;  66 932-935
  CrossrefPubMedGoogle Scholar
• 53 Jackman Jr J D, Simonsen R L. The clinical manifestations of cardiac mucormycosis.  Chest. 1992;  101 1733-1736
  PubMedGoogle Scholar
• 54 Virmani R, Connor D H, McAllister H A. Cardiac mucormycosis: a report of five patients and review of 14 previously reported cases.  Am J Clin Pathol. 1982;  78 42-47
  PubMedGoogle Scholar
• 55 Fong K M, Seneviratne E M, McCormack J G. Mucor cerebral abscess associated with intravenous drug abuse.  Aust N Z J Med. 1990;  20 74-77
  PubMedGoogle Scholar
• 56 Cook B A, White C B, Blaney S M, Bass J W. Survival after isolated cerebral mucormycosis.  Am J Pediatr Hematol Oncol. 1989;  11 330-333
  PubMedGoogle Scholar
• 57 Santos J, Espigado P, Romero C et al.. Isolated renal mucormycosis in two AIDS patients.  Eur J Clin Microbiol Infect Dis. 1994;  13 430-432
  PubMedGoogle Scholar
• 58 Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses.  Mycoses. 2001;  44 253-260
  PubMedGoogle Scholar
• 59 Murphy R A, Miller Jr W T. Pulmonary mucormycosis.  Semin Roentgenol. 1996;  31 83-87
  PubMedGoogle Scholar
• 60 Glazer M, Nusair S, Breuer R et al.. The role of BAL in the diagnosis of pulmonary mucormycosis.  Chest. 2000;  117 279-282
  CrossrefPubMedGoogle Scholar
• 61 Al-Abbadi M A, Russo K, Wilkinson E J. Pulmonary mucormycosis diagnosed by bronchoalveolar lavage: a case report and review of the literature.  Pediatr Pulmonol. 1997;  23 222-225
  CrossrefPubMedGoogle Scholar
• 62 Chandler F W, Watts J C. Zygomycosis. In: Chandler FW, Watts JC Pathologic Diagnosis of Fungal Infections. Vol 1. Chicago; American Society of Clinical Pathologists 1987: 85-96
  Google Scholar
• 63 Ribes J A, Vanover-Sams C, Baker D J. Zygomycetes in human disease.  Clin Microbiol Rev. 2000;  13 236-301
  CrossrefPubMedGoogle Scholar
• 64 Yeo S F, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections.  Clin Microbiol Rev. 2002;  15 465-484
  CrossrefPubMedGoogle Scholar
• 65 Parfrey N A. Improved diagnosis and prognosis of mucormycosis: a clinicopathologic study of 33 cases.  Medicine (Baltimore). 1986;  65 113-123
  PubMedGoogle Scholar
• 66 Yohai R A, Bullock J D, Aziz A A, Markert R J. Survival factors in rhino-orbital-cerebral mucormycosis.  Surv Ophthalmol. 1994;  39 3-22
  CrossrefPubMedGoogle Scholar
• 67 Schmidt J M, Poublon R M. Rhinocerebral mycosis in immunocompromised patients: a case report and review of the literature.  Rhinology. 1998;  36 90-93
  PubMedGoogle Scholar
• 68 Otcenasek M, Buchta V. In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens.  Mycopathologia. 1994;  128 135-137
  CrossrefPubMedGoogle Scholar
• 69 Dannaoui E, Mouton J W, Meis J F, Verweij P E. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.  Antimicrob Agents Chemother. 2002;  46 1953-1959
  CrossrefPubMedGoogle Scholar
• 70 Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela J L. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole.  J Antimicrob Chemother. 2001;  48 919-921
  CrossrefPubMedGoogle Scholar
• 71 Larkin J A, Montero J. Efficacy and safety of amphotericin B lipid complex for zygomycosis.  Infect Med. 2003;  20 201-206
  PubMedGoogle Scholar
• 72 Wali Y A, al Lamki Z, al Kindi H et al.. Case report: successful outcome of invasive nasal sinus zygomycosis in a child with relapsed acute lymphoblastic leukaemia due to liposomal amphotericin B.  Mycoses. 2001;  44 195-199
  CrossrefPubMedGoogle Scholar
• 73 Dannaoui E, Afeltra J, Meis J F, Verweij P E. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.  Antimicrob Agents Chemother. 2002;  46 2708-2711
  CrossrefPubMedGoogle Scholar
• 74 Walsh T J, Hiemenz J W, Seibel N L et al.. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.  Clin Infect Dis. 1998;  26 1383-1396
  CrossrefPubMedGoogle Scholar
• 75 Linden P, Lee L, Walsh T J. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections.  Pharmacotherapy. 1999;  19 1261-1268
  CrossrefPubMedGoogle Scholar
• 76 Ng T T, Denning D W. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data.  Arch Intern Med. 1995;  155 1093-1098
  CrossrefPubMedGoogle Scholar
• 77 Gebhard F, Chastagner P, Maillot D et al.. Favorable outcome of orbital nasal sinus mucormycosis complicating the induction treatment of acute lymphoblastic leukemia [in French].  Arch Pediatr. 1995;  2 47-51
  CrossrefPubMedGoogle Scholar
• 78 Parkyn T, McNinch A W, Riordan T, Mott M. Zygomycosis in relapsed acute leukaemia.  J Infect. 2000;  41 265-268
  CrossrefPubMedGoogle Scholar
• 79 Gaviria J M, Grohskopf L A, Barnes R, Root R K. Successful treatment of rhinocerebral zygomycosis: a combined-strategy approach.  Clin Infect Dis. 1999;  28 160-161
  PubMedGoogle Scholar
• 80 Kfoury A G, Smith J C, Farhoud H H et al.. Adjuvant intrapleural amphotericin B therapy for pulmonary mucormycosis in a cardiac allograft recipient.  Clin Transplant. 1997;  11 608-612
  PubMedGoogle Scholar
• 81 Sun Q N, Fothergill A W, McCarthy D I, Rinaldi M G, Graybill J R. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.  Antimicrob Agents Chemother. 2002;  46 1581-1582
  CrossrefPubMedGoogle Scholar
• 82 Sun Q N, Najvar L K, Bocanegra R, Loebenberg D, Graybill J R. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.  Antimicrob Agents Chemother. 2002;  46 2310-2312
  CrossrefPubMedGoogle Scholar
• 83 Tobon A M, Arango M, Fernandez D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy.  Clin Infect Dis. 2003;  36 1488-1491
  CrossrefPubMedGoogle Scholar
• 84 Greenberg N, Anstead G, Herbrecht R et al.. Posaconazole (POS) experience in the treatment of zygomycosis. Program and abstracts of the 43rd Annual ICAAC Chicago, Illinois; September 14-17, 2003
  Google Scholar
• 85 Mazade M A, Margolin J F, Rossmann S N, Edwards M S. Survival from pulmonary infection with Cunninghamella bertholletiae: case report and review of the literature.  Pediatr Infect Dis J. 1998;  17 835-839
  CrossrefPubMedGoogle Scholar
• 86 McAdams H P, Rosado de Christenson M, Strollo D C, Patz Jr E F. Pulmonary mucormycosis: radiologic findings in 32 cases.  AJR Am J Roentgenol. 1997;  168 1541-1548
  PubMedGoogle Scholar
• 87 Asai K, Suzuki K, Takahashi T et al.. Pulmonary resection with chest wall removal and reconstruction for invasive pulmonary mucormycosis during antileukemia chemotherapy.  Jpn J Thorac Cardiovasc Surg. 2003;  51 163-166
  PubMedGoogle Scholar
• 88 Slavin M A, Kannan K, Buchanan M R, Sasadeusz J, Roberts A W. Successful allogeneic stem cell transplant after invasive pulmonary zygomycosis.  Leuk Lymphoma. 2002;  43 437-439
  CrossrefPubMedGoogle Scholar
• 89 Price J C, Stevens D L. Hyperbaric oxygen in the treatment of rhinocerebral mucormycosis.  Laryngoscope. 1980;  90(5 pt 1) 737-747
  PubMedGoogle Scholar
• 90 Bentur Y, Shupak A, Ramon Y et al.. Hyperbaric oxygen therapy for cutaneous/soft-tissue zygomycosis complicating diabetes mellitus.  Plast Reconstr Surg. 1998;  102 822-824
  PubMedGoogle Scholar
• 91 Ferguson B J, Mitchell T G, Moon R, Camporesi E M, Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis.  Rev Infect Dis. 1988;  10 551-559
  PubMedGoogle Scholar
• 92 Liles W C, Huang J E, van Burik J A, Bowden R A, Dale D C. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens.  J Infect Dis. 1997;  175 1012-1015
  PubMedGoogle Scholar
• 93 Brummer E, Maqbool A, Stevens D A. Protection of bronchoalveolar macrophages by granulocyte-macrophage colony-stimulating factor against dexamethasone suppression of fungicidal activity for Aspergillus fumigatus conidia.  Med Mycol. 2001;  39 509-515
  PubMedGoogle Scholar
• 94 Ma B, Seymour J F, Januszewicz H, Slavin M A. Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF.  Leuk Lymphoma. 2001;  42 1393-1399
  PubMedGoogle Scholar
• 95 Garcia-Diaz J B, Palau L, Pankey G A. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor.  Clin Infect Dis. 2001;  32 e145-e150
  CrossrefPubMedGoogle Scholar
• 96 Maury S, Leblanc T, Feuilhade M, Molina J M, Schaison G. Successful treatment of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia.  Clin Infect Dis. 1998;  26 200-202
  PubMedGoogle Scholar
• 97 Saltoglu N, Tasova Y, Zorludemir S, Dundar I H. Rhinocerebral zygomycosis treated with liposomal amphotericin B and surgery.  Mycoses. 1998;  41 45-49
  PubMedGoogle Scholar

Alison G FreifeldM.D. 

Infectious Diseases Section, Department of Medicine

985400 University of Nebraska Medical Center

Omaha, NE 68198-5400

Email: afreifeld@unmc.edu